Minerva Neurosciences, Inc. (NERV)
NASDAQ: NERV · Real-Time Price · USD
5.87
+0.17 (2.98%)
At close: Apr 14, 2026, 4:00 PM EDT
5.98
+0.11 (1.87%)
After-hours: Apr 14, 2026, 4:32 PM EDT
Minerva Neurosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
7
Market Cap
254.02M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Arcturus Therapeutics Holdings | 82.03M |
| Compugen | 72.76M |
| Coherus Oncology | 42.17M |
| Orchestra BioMed Holdings | 33.48M |
| Alector | 21.05M |
| Sol-Gel Technologies | 19.39M |
| Adagene | 7.67M |
| Camp4 Therapeutics | 3.50M |
NERV News
- 12 days ago - Minerva Announces Leadership Transition - GlobeNewsWire
- 14 days ago - Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia - GlobeNewsWire
- 20 days ago - Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026 - GlobeNewsWire
- 4 weeks ago - Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum - GlobeNewsWire
- 4 weeks ago - Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates - GlobeNewsWire
- 5 weeks ago - Minerva Neurosciences to Participate in The Citizens Life Sciences Conference - GlobeNewsWire
- 2 months ago - Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026 - GlobeNewsWire
- 5 months ago - Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors - GlobeNewsWire